Bioharvest Stock Price, News & Analysis

BioHarvest Sciences (NASDAQ: BHST) announced that sales of its flagship product VINIA, a red grape cell-based supplement, have exceeded $50 million USD in cumulative sales. The majority of these sales occurred since the US launch less than 4 years ago.

The company has achieved over 50,000 active U.S. users on recurring subscription packages, with VINIA receiving approximately 8,000 customer reviews and a verified rating of 4.8/5. Clinical trials have demonstrated VINIA's ability to improve blood flow and arterial dilation.

To support future growth, BioHarvest plans to expand its production capacity by 4x with a new 100-ton per year facility, expected to be operational in late 2026. The company has invested 15 years and over $100M in developing its patented Botanical Synthesis technology, which is now being used in their CDMO Services division for pharmaceutical and nutrition industry partners.

BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the upcoming WeBull Consumer Stocks Virtual Webinar on February 18, 2025, at 2:00 p.m. Eastern time. CEO Ilan Sobel will present the company's investor story, focusing on their patented Botanical Synthesis technology platform.

The presentation will showcase BioHarvest's approach to developing and commercializing plant-based compounds, highlighting the growth of their direct-to-consumer business, including the VINIA® product line, and their CDMO Services business unit. The company aims to demonstrate how their technology impacts various industries, including Nutraceuticals, Pharmaceuticals, Cosmeceuticals, and Nutrition, through the delivery of consistent, economically viable, and patentable plant compounds.

The webinar requires mandatory pre-registration, and a replay link will be available on BioHarvest's investor relations website following the event.

BioHarvest Sciences (NASDAQ: BHST) has appointed Sharon Malka as an independent director, effective immediately. Malka brings over 25 years of financial and capital markets experience to the board. He currently serves as CEO of Dotz Nano and is on the board of MediWound , where he previously held positions as CFO and CEO.

Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division, highlighted Malka's operational experience in advancing innovative technologies and structuring strategic transactions as valuable assets for the company's growth. Malka, a certified CPA with an MBA and Harvard Business School Executive Education, expressed enthusiasm about contributing to BioHarvest's development of science-based therapeutic solutions using its Botanical Synthesis technology.

BioHarvest Sciences (NASDAQ: BHST) released a shareholder letter highlighting key achievements in 2024 and outlook for 2025. The company introduced its new CDMO Services division, partnering with Tate & Lyle for sweetener development. The VINIA® capsule business doubled, with approximately 50,000 active U.S. subscribers and a Q4 2024 run rate of nearly $30 million.

Key developments include the launch of VINIA® Functional Superfood Coffee line, generating $1.6 million in sales since launch, and the acquisition of an 80,000 square foot corporate campus in Yavneh, Israel. Gross margins improved from 44% in Q3 2023 to 56% in Q3 2024, with expectations to exceed 60% in 2025. The company successfully uplisted to Nasdaq and targets adjusted EBITDA profitability in H2 2025.

Tate & Lyle and BioHarvest Sciences (NASDAQ: BHST) have announced a strategic partnership to develop next-generation plant-based ingredients for healthier food and beverages. The collaboration will initially focus on developing botanical sweetening ingredients using BioHarvest's proprietary Botanical Synthesis platform, which produces non-GMO plant-derived ingredients by growing targeted plant cells that mirror and magnify phyto-nutrients without traditional farming.

The partnership aims to create sugar-like sweeteners without aftertaste while using significantly less land and water compared to traditional methods. Tate & Lyle will contribute its sugar reduction expertise, regulatory knowledge, and global customer access, while BioHarvest brings its validated industrial-scale plant cell technology. The collaboration is part of Tate & Lyle's open innovation program to create cutting-edge solutions for the food and beverage industry.

BioHarvest Sciences reported strong Q3 2024 financial results with revenue increasing 101% year-over-year to $6.5 million. Gross margins expanded significantly by 1,200 basis points to 57% compared to 45% in the same year-ago quarter. The company's VINIA® subscribers grew 128% year-over-year, and they successfully launched a new VINIA® SuperFood tea line. Management expects Q4 2024 revenues of at least $7.2 million and projects reaching adjusted EBITDA breakeven in H2 2025. The company recently uplisted to the Nasdaq Global Market on November 12, 2024.

BioHarvest Sciences (NASDAQ: BHST) has launched VINIA® SuperFood Functional Tea Line, targeting the $3.3 billion North American functional tea market. The new product line includes four premium blends: Black Tea, Green Tea, Matcha Green Tea, and Cranberry Hibiscus Herbal Tea, all infused with piceid resveratrol equivalent to one VINIA® capsule. The teas, sourced from Rainforest Alliance certified farms, outperformed leading brands in third-party blind taste testing. This launch follows the successful VINIA® capsules and SuperFood Coffee, implementing the company's 'VINIA® Inside' strategy to deliver circulatory health benefits across multiple consumer verticals.

BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference on December 3, 2024, in Boca Raton, FL. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and deliver a presentation at the event. The company, which specializes in Botanical Synthesis technology, aims to discuss its growth strategy focusing on plant-based molecules for Direct-to-Consumer Health and Wellness business and CDMO customers. The presentation will be made available on BioHarvest's investor relations website following the conference.

BioHarvest Sciences (NASDAQ: BHST) has scheduled its Third Quarter 2024 earnings call for November 25, 2024, at 4:30 P.M. Eastern Time. The company will release its financial results for the quarter ended September 30, 2024, after market close on the same day. The conference call will include a corporate update and a Q&A session. Participants can join via U.S./Canada dial-in (1-844-825-9789) or International dial-in (1-412-317-5180) using Conference ID 10194495. A replay will be available through December 9, 2024.